Crestor vs Leqvio: Head-to-Head Efficacy Comparison

Why No Direct Head-to-Head Trial Exists

Crestor and Leqvio were never designed to compete. Rosuvastatin is a foundational lipid-lowering therapy prescribed as first-line treatment. Inclisiran was developed and tested as add-on therapy for patients already on statins who still carry residual LDL-C burden [1][2]. Comparing them head-to-head would require removing statin therapy from one arm, which would be ethically problematic in high-risk patients who benefit from established statin regimens.

The 2018 ACC/AHA Cholesterol Guideline positions high-intensity statins (rosuvastatin 20-40 mg, atorvastatin 40-80 mg) as the backbone of atherosclerotic cardiovascular disease (ASCVD) risk reduction [3]. Inclisiran, ezetimibe, and PCSK9 monoclonal antibodies all layer on top of that backbone for patients who do not reach target LDL-C. Dr. Christie Ballantyne of Baylor College of Medicine has noted: "Statins remain the foundation. The question with newer agents like inclisiran is not whether they replace statins, but how much additional benefit they add for patients who need more" [4].

Cross-trial comparison remains the only available method. That comparison requires understanding the different patient populations, background therapies, and primary endpoints in JUPITER versus the ORION program.

Rosuvastatin: JUPITER Trial and LDL-C Efficacy

Rosuvastatin 20 mg reduced the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% versus placebo in JUPITER (HR 0.56 to 95% CI 0.46-0.69, P<0.00001) [1]. The trial enrolled 17,802 apparently healthy adults with LDL-C <130 mg/dL but high-sensitivity C-reactive protein (hsCRP) ≥2.0 mg/L. Median follow-up was 1.9 years before the Data Safety Monitoring Board halted the trial early for overwhelming benefit.

LDL-C fell by a median of 50% from baseline in the rosuvastatin arm, reaching a median of 55 mg/dL [1]. The hsCRP reduction of 37% suggested anti-inflammatory effects beyond pure lipid lowering, a finding that reshaped how clinicians think about residual inflammatory risk.

The STELLAR trial (2003) established the dose-response curve for rosuvastatin across 2,431 patients with hyperlipidemia [5]. At 40 mg, rosuvastatin lowered LDL-C by 55%, outperforming atorvastatin 40 mg (47%), simvastatin 40 mg (38%), and pravastatin 40 mg (29%) at equivalent doses. This made rosuvastatin the most potent statin on a milligram-for-milligram basis.

Real-world data confirm these findings hold outside controlled trials. A meta-analysis of 170,000 participants across 26 statin trials (CTT Collaboration, Lancet 2010) demonstrated that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C with statins reduces major vascular events by approximately 22% over five years [6]. That proportional benefit applied consistently regardless of baseline LDL-C or starting cardiovascular risk.

Inclisiran: ORION Program and LDL-C Efficacy

ORION-10 (N=1,561, U.S. patients with ASCVD) and ORION-11 (N=1,617, European patients with ASCVD or ASCVD risk equivalents) tested inclisiran 284 mg versus placebo, both on top of maximally tolerated statin therapy [2]. At day 510 (approximately 17 months), inclisiran reduced LDL-C by 52.3% in ORION-10 and 49.9% in ORION-11 compared to placebo (both P<0.001). Time-averaged LDL-C reductions from day 90 through day 540 were 53.8% and 49.2%, respectively.

These reductions came on top of existing therapy. The critical distinction: patients in both ORION trials were already receiving statins (about 69% on high-intensity statins) and still had LDL-C levels averaging 104-105 mg/dL at baseline [2]. Inclisiran's 50% relative reduction from that starting point translates to an absolute LDL-C drop of roughly 50-53 mg/dL, bringing average LDL-C into the 50-55 mg/dL range.

Durability is a notable feature. A single 284 mg subcutaneous injection maintains LDL-C suppression for approximately six months. The siRNA mechanism silences hepatic PCSK9 messenger RNA production, reducing PCSK9 protein synthesis by about 80% and keeping LDL receptor recycling elevated between doses [7]. Unlike PCSK9 monoclonal antibodies (evolocumab, alirocumab) that require injections every 2-4 weeks, inclisiran's dosing schedule of twice yearly (after the loading phase) may improve long-term persistence.

The FDA approved inclisiran in December 2021 as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who require additional LDL-C lowering [8].

Cross-Trial Efficacy: Putting the Numbers Side by Side

Direct numeric comparisons between JUPITER and ORION carry significant caveats. The populations differ. JUPITER enrolled primary prevention patients with low LDL-C but elevated inflammation. The ORION trials enrolled secondary prevention patients with established ASCVD and elevated LDL-C despite statin use. Endpoint definitions differ. Background therapies differ.

With those disclaimers, here is what the data show when placed adjacent:

LDL-C reduction magnitude: Rosuvastatin 20 mg produced a 50% LDL-C reduction from a baseline of ~108 mg/dL (to ~55 mg/dL) in statin-naive patients [1]. Inclisiran produced a 50-52% LDL-C reduction from a baseline of ~105 mg/dL (to ~50-55 mg/dL) in statin-treated patients [2]. The relative percentage reductions are strikingly similar, but inclisiran achieves its reduction on top of whatever the statin is already doing.

Absolute LDL-C achieved: Both approaches land patients near 50-55 mg/dL in their respective trial populations. For a patient on rosuvastatin 40 mg with a residual LDL-C of 90 mg/dL, adding inclisiran could theoretically reduce LDL-C to approximately 45 mg/dL (a 50% relative reduction from 90).

Cardiovascular events: Rosuvastatin has definitive major adverse cardiovascular event (MACE) data from JUPITER and the CTT meta-analyses [1][6]. Inclisiran does not yet have completed cardiovascular outcomes data. ORION-4, a 15,000-patient outcomes trial comparing inclisiran to placebo on top of standard care, began enrolling in 2018, and results are expected to report by 2026 [9]. The 2022 ACC/AHA Expert Consensus Decision Pathway already positions PCSK9-directed therapies (including inclisiran) for patients with LDL-C ≥70 mg/dL on maximally tolerated therapy and very high ASCVD risk, based on surrogate endpoint data and class-level evidence from PCSK9 monoclonal antibody outcomes trials like FOURIER and ODYSSEY OUTCOMES [10].

Dr. Kausik Ray, lead investigator of the ORION program at Imperial College London, stated: "The consistency of the roughly 50% LDL-C reduction across ORION-9, -10, and -11, maintained over 18 months with twice-yearly dosing, supports inclisiran as a practical long-term option for patients who remain above target on oral therapies" [2].

Safety and Tolerability Differences

Rosuvastatin shares the class-wide statin safety profile. Myalgia occurs in 5-10% of patients across statin trials, though nocebo-controlled studies suggest the true drug-attributable rate is closer to 1-2% [11]. Hepatotoxicity (ALT elevation >3x upper limit of normal) occurs in <1% of patients on rosuvastatin 40 mg [5]. New-onset diabetes risk increases by approximately 9% with intensive statin therapy, an effect confirmed in JUPITER (HR 1.25, P=0.01) and across the CTT meta-analysis [1][12]. Rhabdomyolysis is rare (<0.1%).

Inclisiran's safety profile through 18 months of follow-up showed injection-site reactions as the most common adverse event, occurring in 5% of inclisiran-treated patients versus 0.7% on placebo in ORION-10 [2]. These reactions were predominantly mild (erythema, pain, rash) and did not lead to treatment discontinuation. Liver enzyme elevations, kidney function changes, and platelet counts showed no significant differences between inclisiran and placebo [2]. Inclisiran did not increase new-onset diabetes risk in the ORION trials, though longer follow-up is needed to assess this more definitively.

One practical difference: statin intolerance affects an estimated 7-29% of patients depending on the definition used [13]. For patients with confirmed statin-associated muscle symptoms who cannot tolerate rosuvastatin even at low doses, inclisiran offers an alternative mechanism to lower LDL-C without engaging the HMG-CoA reductase pathway. The ORION-5 trial specifically studied inclisiran in statin-intolerant patients with HeFH and showed a 39.7% LDL-C reduction [14].

Combination Strategy: Using Both Together

Current treatment algorithms do not frame rosuvastatin and inclisiran as either/or choices. The standard sequence for ASCVD risk reduction follows a stepwise escalation:

Step 1 is high-intensity statin therapy (rosuvastatin 20-40 mg or atorvastatin 40-80 mg). Step 2 adds ezetimibe if LDL-C remains ≥70 mg/dL (or ≥55 mg/dL per European Society of Cardiology 2019 guidelines) [3][15]. Step 3 adds a PCSK9-directed therapy, either a monoclonal antibody (evolocumab, alirocumab) or inclisiran.

The 2022 ACC Expert Consensus recommends PCSK9-directed therapies specifically for very high-risk ASCVD patients (recent ACS, multiple prior events, or polyvascular disease) with LDL-C ≥55 mg/dL despite maximally tolerated statin plus ezetimibe [10]. In this pathway, a patient might take rosuvastatin 40 mg daily, ezetimibe 10 mg daily, and receive inclisiran 284 mg every six months, a regimen that could theoretically lower LDL-C by 75-85% from the untreated baseline.

The ORION-3 open-label extension followed patients for up to four years on inclisiran added to statin background therapy and showed sustained LDL-C reductions of approximately 45% with no attenuation of effect or accumulation of safety signals over time [16].

Cost-Effectiveness and Access

The economic gap between these two agents is enormous. Generic rosuvastatin costs approximately $4-12 per month ($50-150 per year) at most U.S. pharmacies [17]. Leqvio carries a wholesale acquisition cost of approximately $3,250 per injection, or $6,500 per year for the maintenance phase (two injections annually) [8]. During the first year, which includes three injections (day 1, day 90, day 270), the cost rises to approximately $9,750.

Insurance coverage for Leqvio varies. Medicare Part B covers it as a physician-administered injectable, which removes the prior authorization barriers that historically slowed access to PCSK9 monoclonal antibodies covered under pharmacy benefit (Part D) [8]. Commercial coverage typically requires documentation of statin intolerance or failure to reach LDL-C goals on maximally tolerated oral therapy.

The Institute for Clinical and Economic Review (ICER) assessed inclisiran's value-based price at approximately $3,600-$6,000 per year, roughly aligning with its current list price, contingent on confirmation of cardiovascular outcomes benefit from ORION-4 [18]. Without positive outcomes data, the cost per quality-adjusted life year (QALY) remains uncertain.

For the large majority of patients with hyperlipidemia, rosuvastatin or another high-intensity statin will remain the appropriate first treatment. Inclisiran fills a specific gap: the patient who has tried adequate statin therapy, added ezetimibe, and still cannot reach guideline-recommended LDL-C targets.

Adherence and Persistence: The Practical Dimension

Statin nonadherence is one of the largest unsolved problems in cardiovascular prevention. A 2019 meta-analysis in the European Heart Journal found that only 49% of patients remained adherent to statin therapy at two years [19]. Poor adherence correlates directly with increased MACE. Each 10% decrease in statin adherence associates with a 1-2% increase in LDL-C levels over time.

Inclisiran's twice-yearly in-office injection model could fundamentally change this dynamic. The patient receives the injection at a scheduled healthcare visit. There are no daily pills to forget, no prescriptions to refill. ORION-10 and ORION-11 reported adherence rates exceeding 95% through 18 months, though this occurred in a controlled trial setting [2].

Whether real-world adherence to scheduled injections every six months will match trial performance is an open question. Patients must still attend their injection appointments. But removing the daily behavioral demand of taking a pill likely confers a meaningful advantage for the subset of patients whose LDL-C elevation is driven partly by inconsistent statin use.